The Surge of CG Oncology: A Stock Worth Watching

This report, penned by the experienced hand of Brad Canino at Guggenheim, initiated the coverage of CG Oncology stock. Canino, with decades of industry insight, bestowed a ‘buy’ rating on the company, suggesting a future where the stock might double, setting a price target of $90. It was a bold claim, one based not on speculation but on tangible potential. He wasn’t just selling a dream, he was selling the promise of a world where CG Oncology could hold a decisive place.

Bitcoin Drama: Woke Wars or Just Tech Tantrums? 🍿

So, apparently, the tech bros are now throwing around the word “woke” like it’s confetti at a Pride parade. 🌈 But hold up-what does being woke have to do with Bitcoin? 🤔 Well, according to some Knots enthusiasts, Bitcoin Core is *so* woke it’s practically sipping oat milk lattes while coding. 🥛

The Elusive Dance of Viasat’s Ascent: A Market Reflection

Just before the market bell had even rung, the company made an announcement that struck at the heart of any seasoned investor’s sensibilities: Viasat had secured a contract with the U.S. Space Force, one of the most reliable and well-funded clients imaginable. This is no mere client, but an entity whose coffers, though often veiled in secrecy, are large enough to carry the weight of ambition and power. Viasat was to design and develop a satellite system that would serve as part of a broader initiative-one that would, in time, build a network of satellites orbiting the earth.

Carolina Wealth Makes a Big $6 Million Bet on Novo Nordisk (NYSE: NVO)

Carolina Wealth Advisors, LLC recently increased its investment in Novo Nordisk. A filing with the Securities and Exchange Commission (SEC) shows they added 102,629 shares during the July-September quarter of 2025. This purchase was worth approximately $6.01 million, based on average share prices during that period. As of October 7, 2025, Carolina Wealth Advisors now holds a total of 116,973 shares of Novo Nordisk.